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Abstract
Background: Prevention of serious infections in preterm infants is a challenge, since prematurity and low birth weight often
requires many interventions and high utility of devices. Furthermore, the possibility to administer enteral nutrition is limited due
to immaturity of the gastrointestinal tract in the presence of a developing immune system. In combination with delayed intestinal
bacterial colonisation compared with term infants, this may increase the risk for serious infections. Acidic and neutral
oligosaccharides play an important role in the development of the immune system, intestinal bacterial colonisation and functional
integrity of the gut. This trial aims to determine the effect of enteral supplementation of acidic and neutral oligosaccharides on
infectious morbidity (primary outcome), immune response to immunizations, feeding tolerance and short-term and long-term
outcome in preterm infants. In addition, an attempt is made to elucidate the role of acidic and neutral oligosaccharides in
postnatal modulation of the immune response and postnatal adaptation of the gut.
Methods/Design: In a double-blind placebo controlled randomised trial, 120 preterm infants (gestational age <32 weeks and/
or birth weight <1500 gram) are randomly allocated to receive enteral acidic and neutral oligosaccharides supplementation
(20%/80%) or placebo supplementation (maltodextrin) between day 3 and 30 of life. Primary outcome is infectious morbidity
(defined as the incidence of serious infections). The role of acidic and neutral oligosaccharides in modulation of the immune
response is investigated by determining the immune response to DTaP-IPV-Hib(-HBV)+PCV7 immunizations, plasma cytokine
concentrations, faecal Calprotectin and IL-8. The effect of enteral acidic and neutral oligosaccharides supplementation on
postnatal adaptation of the gut is investigated by measuring feeding tolerance, intestinal permeability, intestinal viscosity, and
determining intestinal microflora. Furthermore, short-term and long-term outcome are evaluated.
Discussion: Especially preterm infants, who are at increased risk for serious infections, may benefit from supplementation of
prebiotics. Most studies with prebiotics only focus on the colonisation of the intestinal microflora. However, the pathways how
prebiotics may influence the immune system are not yet fully understood. Studying the immune modulatory effects is complex
because of the multicausal risk of infections in preterm infants. The combination of neutral oligosaccharides with acidic
oligosaccharides may have an increased beneficial effect on the immune system. Increased insight in the effects of prebiotics on
the developing immune system may help to decrease the (infectious) morbidity and mortality in preterm infants.
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Background
Preterm infants are at increased risk for the development
of serious nosocomial infections, especially very low birth
weight infants at a NICU [1]. In a recent review of the lit-
erature, we found that the intestinal bacterial colonisation
in preterm infants is much more diverse than in term
infants and that antibiotics cause a significant delay in the
intestinal bacterial colonisation [2]. Furthermore, the pos-
sibility to administer enteral nutrition is limited due to
immaturity of the gastrointestinal tract in the presence of
a developing immune system.
Human milk has anti-inflammatory effects and bifidog-
enic effects on the intestinal microflora [3,4]. Term breast-
fed infants have less infections and develop less atopy
compared with formula fed infants [5,6]. Many factors
have been implicated in this effect, including human milk
oligosaccharides [7,8]. Many attempts have been made to
mimic this effect of human milk. Addition of prebiotics,
consisting of neutral oligosaccharides, to infant formula
has been found to show potential advantageous effects in
term and preterm infants [9,10]. Besides neutral oligosac-
charides, breast milk also contains acidic oligosaccharides
[8]. In the past, research has mainly focussed on neutral
oligosaccharides such as galacto-oligosaccharides and
fructo-oligosaccharides (GOS/FOS). Supplementation of
GOS/FOS in term and preterm infants results in: 1. Stim-
ulation of a bifidogenic intestinal flora [11,12]; 2. Reduc-
tion of pathogens in the intestine [12]; 3. Production of
beneficial fermentation metabolites such as short chain
fatty acids (SCFA) [10]; 4. Decrease of stool pH [13]; 5.
Improved intestinal physiology (stool characteristics,
motility) [14]; 6. Less infections and atopy [15,16].
In breast milk 80% of the oligosaccharides are neutral (as
in GOS/FOS), and 20% are acidic. Acidic oligosaccharides
(AOS) can be derived from carrots with their active com-
ponent pectin. Pectin is a common structural component
of all higher plants. Cooking of pectin-containing vegeta-
bles induces the cleavage of the long-chain pectin poly-
mers into acidic oligosaccharides. For already nearly 100
years, carrots are known to have health promoting effects.
In 1908, carrot soup was used as treatment of diarrhoea
[17]. In 1997, Guggenbichler identified the anti-adhesive
effect of acidic oligosaccharides [18].
The combination of acidic and neutral oligosaccharides
may have several advantageous effects [10,19-21]: 1.
Improvement of the response to immunizations; 2. Stim-
ulation of Th1 cytokine response (e.g. TNF-α, IFN-
gamma) and decreasing the Th2 cytokine release (e.g. IL-
10, IL-4, IL-5); 3. Stimulation of a bifidogenic intestinal
flora; 4. Preventing adhesion of pathogens to epithelial
tissues.
As a result of these effects, we hypothesise that preterm
infants receiving a combination of GOS/FOS with AOS
may have: 1. Less infections; 2. Better response to immu-
nizations; 3. Less atopy later in life; 4. Less feeding intol-
erance.
As infections are still a major cause of morbidity and mor-
tality in preterm infants, reducing the incidence of serious
infections is very important. Controversy exists on the def-
initions for serious infections in neonates. Therefore in a
previous study, we adjusted the criteria of the Centers for
Disease Control and Prevention for serious infections in
children < 1 year for use in neonates [1], and found in a
prospective study these criteria applicable in preterm
infants [22].
In conclusion, this double-blind randomised controlled
trial aims to determine the effect of enteral supplementa-
tion of acidic and neutral oligosaccharides on infectious
morbidity (primary outcome), immune response to
immunizations, feeding tolerance and short-term and
long-term outcome in preterm infants. In addition, an
attempt is made to elucidate the role of acidic and neutral
oligosaccharides in postnatal modulation of the immune
response and postnatal adaptation of the gut.
Methods/Design
The study is designed as a double-blind placebo control-
led randomised clinical trial. Approval of the study proto-
col by the medical ethical review board of VU University
Medical Center Amsterdam is obtained before the start of
the study.
Study population
Infants with a gestational age <32 weeks and/or birth
weight <1500 gram admitted to the level III neonatal
intensive care unit (NICU) of the VU University Medical
Center, Amsterdam, are eligible for participation in the
study. Written informed consent is obtained from all par-
ents.
Exclusion criteria are: major congenital or chromosomal
anomalies, death <48 hours after birth, transfer to another
hospital <48 hours after birth and admission from an
extra regional hospital.
Treatment allocation and blinding
To balance birth weight distribution into treatment
groups, each infant is stratified to one of three birth
weight groups (≤ 799 g, 800–1199 g, ≥ 1200 g) and ran-
domly allocated to treatment within 48 hours after birth.
An independent researcher uses a computer-generated
randomisation table (provided by Danone Research, Frie-
drichsdorf, Germany) to assign infants to treatment N or
O. Investigators, parents, medical and nursing staff areBMC Pediatrics 2008, 8:46 http://www.biomedcentral.com/1471-2431/8/46
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unaware of treatment allocation. The randomisation code
is broken after data analysis is performed.
Treatment
Acidic and neutral oligosaccharides powder and the pla-
cebo powder (maltodextrin) are prepared by Danone
Research, Friedrichsdorf, Germany and are packed sterile.
During the study period, acidic and neutral oligosaccha-
rides and placebo powder are monitored for stability and
microbiological contamination.
Between days 3 and 30 of life, acidic and neutral oligosac-
charides supplementation (20%/80% mixture) is admin-
istered in a dose of maximal 1.5 g/kg/day to breast milk or
preterm formula in the intervention group. Two members
of the nursing staff daily add supplementation to breast
milk or to preterm formula (Nenatal Start®, Nutricia Ned-
erland B.V., Zoetermeer, The Netherlands), according to
the parents' choice. Per 100 mL, Nenatal Start® provides 80
kcal, 2.4 g protein (casein-whey protein ratio 40:60), 4.4
g fat, and 7.8 g carbohydrate. When infants are transferred
to another hospital before the end of the study, the proto-
col is continued under supervision of the principal inves-
tigator (EW).
Nutritional support
Protocol guidelines for the introduction of parenteral and
enteral nutrition follow current practice at our NICU.
Nutritional support is administered as previously
described [23].
For each infant in the study, a feeding schedule is pro-
posed based on birth weight and the guidelines as men-
tioned above. However, the medical staff of our NICU has
final responsibility for the administration of parenteral
nutrition and advancement of enteral nutrition.
After discharge all infants receive breast milk or preterm
formula Nenatal Start (without GOS/FOS)® until term,
and Nenatal 1 (without GOS/FOS)® until the corrected age
of 6 months.
Study outcome measures
Clinical outcome measures
Primary outcome of the study is the effect of acidic and
neutral oligosaccharides (20%/80% mixture) supple-
mented to the enteral nutrition on infectious morbidity as
previously defined [1,22]. The occurrence of serious infec-
tions is determined by two investigators, unaware of treat-
ment allocation, as previously described [1,22].
The following perinatal characteristics are registered to
assess prognostic similarity: maternal age and race, obstet-
ric diagnosis, administration of antenatal steroids and
antibiotics, mode of delivery, sex, gestational age, birth
weight, birth weight <10th percentile [24], Apgar scores,
pH of the umbilical artery, clinical risk index for babies
[25], and administration of surfactant.
During the study period, actual intake of enteral and
parenteral nutrition, powder supplementation and type of
feeding (breast milk or preterm formula) are recorded
Table 1: Clinical outcome measures
Remarks
Infectious morbidity
Serious infections Primary outcome
Number of infectious episodes
Cultured micro-organisms
Feeding tolerance
Enteral feeding >120 mL/kg/day
Age at finishing parenteral nutrition
Necrotising enterocolitis Bell et al.[35]
Short-term outcome
Weight z scores at birth, day 30 and at discharge Usher et al. [24]
Patent ductus arteriosus
Ventilatory support
Use of oxygen at postmenstrual age of 36 weeks Jobe et al. [36]
Intraventricular hemorrhage Papile et al. [37]
Retinopathy of prematurity Committee for ROP. [38]
Death
Age at discharge from NICU and age at discharge home
ROP = retinopathy of prematurity; NICU = neonatal intensive care unite.BMC Pediatrics 2008, 8:46 http://www.biomedcentral.com/1471-2431/8/46
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daily. Feeding tolerance and short-term outcome are eval-
uated. (Table 1)
Immune response
The effect of acidic and neutral oligosaccharides supple-
mented enteral nutrition on the immune response is
investigated, in collaboration with the National Institute
for Public Health and Environment, by determining the
development of the immune response to DTaP-IPV-Hib(-
HBV) + PCV7 immunizations (after the first 3 doses), and
the development of the memory function of the immune
response to these immunizations by measuring the
response after the 4th  booster dose. In addition, the
plasma cytokine concentrations (Il-2, Il-4, IL-5, Il-8, IL-10,
TGF, IFN), faecal Calprotectin measured by ELISA (Buhl-
mann, Switzerland), and IL8 measured by random-access
chemiluminescence immunoassay (Siemens, The Nether-
lands) are determined.
Postnatal adaptation of the gut
The effect of acidic and neutral oligosaccharides supple-
mented enteral nutrition on postnatal adaptation of the
gut is studied by measuring feeding tolerance, intestinal
permeability, intestinal microflora and intestinal viscos-
ity.
Intestinal permeability is measured by the sugar absorp-
tion test [26]. After instillation of the test solution, 2 mL/
kg by nasogastric tube, urine is collected for 6 hours. After
collection, 0.1 mL chlorohexidine digluconate 20% (pre-
servative) is added to the urine and samples are stored at
-20°C until analysis. Lactulose and mannitol concentra-
tions (mmol/mol creatinine) are measured by gas chro-
matography as previously described [27]. The lactulose/
mannitol ratio is calculated and used as a measure of
intestinal permeability.
Faecal samples are stored at -20°C until analysis by fluo-
rescent in situ hybridisation (FISH) using specific 16S
rDNA-targeted [28]. Intestinal viscosity is measured by
high-pressure capillary rheometry (viscosimetry) as
described by Mihatsch et al. [14].
Long-term outcome
To determine the incidence of allergic and infectious dis-
ease in the first year of life standardized questionnaires
will be sent to the parents prior to the follow-up visit at
the corrected age of 1 year [29]. Faecal samples (FISH, Cal-
protectin and IL-8) and IgE/IgG4 levels in blood will be
measured at the age of 5 and 12 months.
To investigate neurodevelopmental outcome, neurologi-
cal status, vision, hearing and Mental Development Index
(MDI) and Psychomotor Development Index (PDI) of the
Bayley Scales of Infant Development II (BSID-II) at the
corrected age of 1 and 2 years (as part of the regular fol-
low-up of NICU infants) are assessed [30,31].
To determine the frequency of side-effects after the first 4
immunizations, standardized questionnaires will be
given to the parents at the time of immunizations. (Table
2)
Sample size
Based on the differences in incidences in infectious mor-
bidity (76% and 50% respectively) in the GEEF study
[22], and a two-tailed α = 0.05, β = 0.20, a sample size of
2 × [2*7.85*0.63(0,37)]/(0,26)2 = 2 × 54 infants is calcu-
Table 2: Study Schedule
< 48 h Day 4 day 7 day 14 day 30 5 months 1 year 2 year
Immune response
Response to immunizations xx
Cytokine response x x x x x
Faecal Calprotectin/IL-8 x x x x x x
Postnatal adaptation of the gut
Intestinal permeability x x x
Intestinal microflora x x x x x x
Intestinal viscosity xxx
Long-term outcome
IgE/IgG4 x x x
Allergic and infectious diseases x
Side effects immunizations†
Neurodevelopment xx
†Standardized questionnaires (Preparedness and Response Unit, Centre for Infectious disease Control Netherlands, National Institute for Public 
Health and the Environment, The Netherlands) after the 1st, 2nd, 3rd and 4th immunization.BMC Pediatrics 2008, 8:46 http://www.biomedcentral.com/1471-2431/8/46
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lated. Based on an expected drop-out rate of 10% during
the study period 2 × 60 infants will be included.
Statistical analysis
To determine whether randomisation is successful, prog-
nostic similarity (perinatal and nutritional characteristics)
between treatment groups is assessed. The Students' t-test,
Mann-Whitney U test, and chi-square test or Fisher's exact
test are used to compare continuous normally distributed,
nonparametric continuous and dichotomous data respec-
tively.
Logistic regression is performed to examine whether
acidic and neutral oligosaccharide supplemented enteral
nutrition decreases the incidence of serious infections. In
an additional analysis, adjustments are made for possible
confounding factors such as administration of antenatal
corticosteroids, birth weight <10th percentile and admin-
istration of breast milk. Analyses of secondary outcomes
(only crude) is performed by Students' t- test, Mann-Whit-
ney U test, chi-square test or Fisher's exact test for
(non)parametric continuous, dichotomous data and
time-dependent data respectively.
Generalised estimated equations [32] are used to analyse
differences and changes over time in plasma cytokine con-
centrations, faecal Calprotectin and IL-8, intestinal per-
meability, intestinal microflora and intestinal viscosity.
Differences of optimal and non-optimal neuromotor
development and normal and abnormal mental/motor
development in oligosaccharides and control groups is
examined by logistic regression with adjustments for pos-
sible confounding factors as gestational age and birth
weight.
All statistical analyses are performed on an intention to
treat basis. In addition, alternative per protocol analyses
are performed, excluding all patients who are not treated
according to protocol, defined as more than 3 consecutive
days or a total of 5 days on minimal enteral feeding or
without supplementation. For all statistic analyses a p
value <0.05 is considered significant (two-tailed). SPSS
15.0 (SPSS Inc., Chicago, IL, USA) is used for data analy-
sis.
Discussion
There is increasing evidence that prebiotics play an impor-
tant role in the development of the intestinal microflora
and the immune system, and may help to decrease the risk
of infectious diseases. Especially preterm infants, who are
at increased risk for serious infections, may benefit from
supplementation of prebiotics. Most studies with prebiot-
ics only focus on the colonisation of the intestinal micro-
flora. The influence on the immune system is not yet fully
understood [33]. Studying the immune modulatory
effects is complex because of the multicausal risk of infec-
tions in preterm infants [34]. The combination of neutral
oligosaccharides with acidic oligosaccharides may have an
increased beneficial effect on the immune system of pre-
term infants due to the specific conditions in the luminal
part of the developing gut wall. Not only the immune
effects, such as morbidity due to infections and response
to immunizations will be investigated, but also other
signs and symptoms such as feeding tolerance, short-term,
long-term and postnatal adaptation of the gut (intestinal
microflora, intestinal permeability, intestinal viscosity).
Increased insight in the effects of prebiotics on the devel-
oping immune system may help to find ways to decrease
the (infectious) morbidity and mortality in preterm
infants.
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